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Abstract
Introduction Intoxications with carbachol, a muscarinic
cholinergic receptor agonist are rare. We report an interesting
case investigating a (near) fatal poisoning.
Methods The son of an 84-year-old male discovered a
newspaper report stating clinical success with plant extracts in
Alzheimer's disease. The mode of action was said to be
comparable to that of the synthetic compound 'carbamylcholin';
that is, carbachol. He bought 25 g of carbachol as pure
substance in a pharmacy, and the father was administered 400
to 500 mg. Carbachol concentrations in serum and urine on day
1 and 2 of hospital admission were analysed by HPLC-mass
spectrometry.
Results Minutes after oral administration, the patient developed
nausea, sweating and hypotension, and finally collapsed.
Bradycardia, cholinergic symptoms and asystole occurred.
Initial cardiopulmonary resuscitation and immediate treatment
with adrenaline (epinephrine), atropine and furosemide was
successful. On hospital admission, blood pressure of the
intubated, bradyarrhythmic patient was 100/65 mmHg. Further
signs were hyperhidrosis, hypersalivation, bronchorrhoea, and
severe miosis; the electrocardiographic finding was atrio-
ventricular dissociation. High doses of atropine (up to 50 mg per
24 hours), adrenaline and dopamine were necessary. The
patient was extubated 1 week later. However, increased
dyspnoea and bronchospasm necessitated reintubation.
Respiratory insufficiency was further worsened by Proteus
mirabilis infection and severe bronchoconstriction. One week
later, the patient was again extubated and 3 days later was
transferred to a peripheral ward. On the next day he died,
probably as a result of heart failure. Serum samples from the first
and second days contained 3.6 and 1.9 mg/l carbachol,
respectively. The corresponding urine concentrations amounted
to 374 and 554 mg/l.
Conclusion This case started with a media report in a popular
newspaper, initiated by published, peer-reviewed research on
herbals, and involved human failure in a case history, medical
examination and clinical treatment. For the first time, an
analytical method for the determination of carbachol in plasma
and urine has been developed. The analysed carbachol
concentration exceeded the supposed serum level resulting
from a therapeutic dose by a factor of 130 to 260. Especially in
old patients, intensivists should consider intoxications (with
cholinergics) as a cause of acute cardiovascular failure.
Introduction
Carbachol is a muscarinic cholinergic receptor agonist discov-
ered in 1932 [1]. It retains substantial nicotinic activity, partic-
ularly on autonomic ganglia. It is likely that both its peripheral
and its ganglionic actions are due, at least in part, to the
release of endogenous acetylcholine from the terminals of
cholinergic fibres [2]. Its clinical use in the treatment of urinary
bladder disorders or gastrointestinal atony has, however,
diminished. Today, carbachol (1 to 3%) is mainly used as eye
drops to lower intraocular pressure in glaucoma.
We report an interesting case of an accidental carbachol
ingestion leading to massive intoxication.
HPLC = high-performance liquid chromatography; LC-MS/MS, liquid chromatography – tandem mass spectrometry.Critical Care    Vol 10 No 3    Schulz et al.
Page 2 of 4
(page number not for citation purposes)
Case report
The son of an 84-year-old male discovered a media report in
Germany's most popular daily newspaper stating clinical suc-
cess with plant extracts (Salvia lavandulaefolia (Spanish sage)
and Melissa officinalis (lemon balm), among others) in Alzhe-
imer's disease. According to this report, the mode of action of
these extracts are said to be comparable to the synthetic com-
pound 'carbamylcholin'; that is, carbachol.
Approaching a pharmacy for a medicine containing this drug,
he was informed that all such brand products were prescrip-
tion-only. However, he was told that this holds true only for the
registered medicines but not for the substance. Eventually, he
ordered and bought 25 g of carbachol as pure substance.
Eleven days later, the patient was administered a teaspoon
equivalent to 400 to 500 mg of carbachol (the average
parenteral therapeutic dose is 1 mg). Minutes later, he devel-
oped nausea, sweating and hypotension, and finally collapsed.
The emergency physician observed bradycardia and choliner-
gic symptoms. Some minutes later asystole occurred. The
physician initiated cardiopulmonary resuscitation, immediately
injecting 3 × 1 mg of adrenaline (epinephrine), 2 × 0.5 mg of
atropine and 80 mg of furosemide (at that time, cholinergic/
carbachol intoxication was not diagnosed; the rationale for
administering furosemide was suspicion of left ventricular fail-
ure). He was intubated and ventilated, and cardiac output
returned.
On hospital admission, 0.5 mg of atropine was injected intra-
venously and 60 g of activated charcoal as well as 60 ml of lac-
tulose were administered through a nasogastric tube
(although diarrhoea might be expected after cholinergic poi-
soning, a laxative was administered to avoid constipation and
hence prolonged absorption of carbachol as a result of atro-
pine therapy). On the intensive care unit, the blood pressure of
the bradyarrhythmic patient was 100/65 mmHg and the heart
rate was 60 beats/minute. Further signs were hyperhidrosis,
hypersalivation, bronchorrhoea, and severe miosis; the elec-
trocardiographic finding was atrio-ventricular dissociation. The
remaining physical examination was unremarkable.
On the first day, a total of 50 mg atropine (2 mg/hour) and a
perfusion of adrenaline and dopamine were necessary.
Significant laboratory test results were as follows: leukocyte
count (WBC) 14.4 × 109/l (peaking at 22.0 × 109/l), platelet
count 250 × 109/l, haemoglobin 12.5 g/dl (trough at 11.0 g/
dl), serum creatinine 221 µmol/l (peaking at 292 µmol/l), urea
33.3 mmol/l, total protein 55 g/l, C-reactive protein 35 mg/l
(peaking at 208 mg/l), and blood glucose 12.5 mmol/l.
Chest X-ray on admission and during the first part of the treat-
ment showed no signs of inhalation pneumonia.
After administration of decreasing doses of atropine, adrena-
line and dopamine, the patient was extubated 1 week later.
However, increasing dyspnea and bronchospasm necessi-
tated reintubation. A bronchopulmonary infection, identified in
the tracheal secretion as Proteus mirabilis, was treated with
ampicillin/sulbactam, severe bronchoconstriction with salb-
utamol, theophylline, and high doses of prednisolone.
One week later, the patient was again extubated and three
days later transferred to a peripheral ward. On the next day he
died. As the respiratory situation was considerably improved
and sepsis signs were not observed, death was most probably
related to heart failure.
Known diseases were Alzheimer's disease, heart failure and
diabetes type 2.
Ambulatory care medication was piracetam, furosemide, cap-
topril, metformin and glyburide.
We obtained written consent and permission to publish this
case, signed by the son of the patient.
Analytical method
Carbachol (INN; 2-carbamoyloxyethyl)trimethylammonium
chloride; IUPAC, Mr 182.65) is a strong base containing a
quaternary nitrogen atom, usually not extractable with organic
solvents and showing no characteristic ultraviolet absorption.
In addition, gas-chromatographic quantification of this com-
pound is not possible. To the best of our knowledge, levels of
carbachol in blood, serum or urine in humans have never been
analysed. Both pharmacokinetic and toxicokinetic data of car-
bachol in human are therefore generally lacking. Hence, a spe-
cific method for the determination of carbachol in human blood
and urine by HPLC-mass spectrometry (liquid chromatogra-
phy – tandem mass spectrometry (LC-MS/MS)) was devel-
oped: to 0.1 ml of serum, 0.8 ml of bidest water, 0.1 ml of
2.5% ammonia and 0.001 mg of triethylbenzylamine as the
internal standard were added. After centrifugation (1 minute at
10,000  g), the supernatant was extracted by solid-phase
extraction with the use of cation-exchange columns (Bond
Elut® CBA; Varian, Darmstadt, Germany). The cartridges were
conditioned with 2 × 1 ml of methanol and 2 × 1 ml of water,
followed by loading with the supernatant. After rinsing sequen-
tially with 1 ml of water, 1 ml of methanol and 1 ml of water,
elution was performed with 1 ml of 0.05 mol/l HCl; 0.01 ml of
the eluate was injected into the LC-MS/MS system (LCQ
DUO; Thermo Finnigan, Egelsbach, Germany). HPLC was
performed with a 2 mm × 15 cm C18 reverse-phase silica col-
umn (SymmetryShield®; Waters, Eschborn, Germany). The
mobile phase used was 0.001 mol/l formic acid at a flow rate
of 0.1 ml/minute. For validation, calibration curves with spiked
plasma were analysed and were linear over a concentration
range of 0.5 to 7.0 mg/l carbachol (r = 0.993), and the limit of
quantification was less than 0.02 mg/l.Available online http://ccforum.com/content/10/3/R84
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Peaks of carbachol (m/z 147) and internal standard (m/z 192)
were detected and identified by electrospray positive ionisa-
tion (+cESI) MS/MS and quantified by integration of fragment
ions at m/z 60 + 88 and m/z 91 + 100, respectively.
For urine analysis, samples could be used without solid-phase
extraction but had to be diluted 1:1,000. After the addition of
appropriate amounts of internal standard, LC-MS/MS was
performed as described for serum.
Analytical results
Serum samples of the first and second days of hospital admis-
sion contained 3.6 and 1.9 mg/l carbachol, respectively. The
corresponding urine concentration amounted to 374 and 554
mg/l.
Discussion
Intoxications with carbachol are rare. The first was described
in 1944: a man died after injection of an ampoule containing
carbachol in crystal form not intended for internal use [3].
A 10-year-old boy was fatally poisoned by his mother, who
added 15 to 20 mg of carbachol to his soup several times. Her
36-year-old husband was treated because of life-threatening
attacks of profuse sweating, intestinal cramps, explosive defe-
cation, hypothermia, hypotension and bradycardia. From that
case, a lethal dose in children of 1 mg/kg has been suggested
[4]. The lethal dose in mice after oral administration is 0.25
mg/kg [1].
After subcutaneous injection of a therapeutic dose, a patient
developed vomitus, severe central chest pain, increasing
breathlessness and eventually esophageal rupture. He died
24 days later [5].
Even administering one or two eye drops containing 2 to 3%
carbachol can result in severe systemic adverse effects result-
ing from absorption in the nasolacrimal duct [6,7].
Assuming a maximum volume of distribution of 1 l/kg, a
parenteral administered therapeutic dose of 1 mg of carbachol
would have resulted in a serum concentration of about 0.014
mg/l. The analysed concentration in this case exceeded the
supposed serum level resulting from a therapeutic dose by a
factor of 130 to 260. This might explain the continuous bron-
choconstriction and possibly neuromuscular insufficiency
even 1 week after extubation.
Dispensing carbachol as a pure substance in a community
pharmacy to a customer seems unbelievable. Eventually, the
charge by the investigating agency (police and prosecution)
was dropped because the individual person in the pharmacy
dispensing carbachol to the patient's son could not be identi-
fied and the supervising pharmacist was fined.
It is remarkable how thoughtless and irresponsible journalists
are in reporting on research in the lay press, taking the cholin-
ergic effects of high concentrations of herbal extracts in vitro
[8] and postulating the clinical benefit in Alzheimer's disease.
Comparing the mode of action with 'carbamylcholin' prompted
the son to seek this medicine to help his father.
Finally, researchers, peer reviewers, and publishers need to be
reminded of their responsibilities before extrapolating labora-
tory findings and suggesting the use of herbals in a disease
such as dementia [9-11]. Today, such publications [10] are
easily available through the Internet [12].
Conclusion
We describe a case of an unintentional carbachol intoxication
in an 84-year-old male patient with known heart failure and dia-
betes, and at an advanced stage of Alzheimer's disease.
Although initial cardiopulmonary resuscitation was successful,
the patient presented severe persistent cholinergic symptoms
complicated by respiratory infection. He eventually died. For
the first time, carbachol serum and urine concentrations were
analysed by HPLC-mass spectrometry, and the serum level
was found to exceed the supposed level resulting from a ther-
apeutic dose by a factor of 130 to 260. Especially in old
patients, emergency and intensive care physicians should
consider intoxications (with cholinergics) as a cause of acute
cardiovascular failure.
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